Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection.
BACKGROUND
Lower respiratory tract infection caused by respiratory syncytial virus (RSV) is in part an immune-mediated disease. For that reason corticosteroids might be effective, especially in patients with severe RSV lower respiratory tract infection. Our aim was to assess the effect of dexamethasone on tracheal viral load and airway inflammation in patients with RSV infection.


METHODS
Mechanically ventilated children with proven RSV infection were randomized to receive dexamethasone (0.6 mg/kg/day in four doses for 48 h) or placebo. Daily tracheal aspirates were analyzed for viral load (by quantitative polymerase chain reaction), interleukin (IL)-8 and white blood cell count.


RESULTS
The RSV RNA concentrations decreased in a similar manner from baseline in the dexamethasone (9 patients) and in the placebo group (13 patients). IL-8 decreased from baseline in the dexamethasone group but increased in the placebo group during the first 48 h [change from baseline at 24 h, -2.3 vs. 0.9 ln ng/ml (95% confidence interval for difference, -4.2 to 0.3, P = 0.02) and at 48 h, -4.2 vs. 0.4 ln mg/ml (95% confidence interval for difference, -5.3 to -0.3; P = 0.03), respectively], without effect on the tracheal white blood cell count.


CONCLUSIONS
Dexamethasone does not cause an impaired decline of tracheal RSV but lowers IL-8 of children mechanically ventilated for RSV lower respiratory tract infection, potentially leading to less inflammation and reduced phagocyte activation.
van Woensel
Job B
JB
Academic Medical Center, Emma Children's Hospital, Pediatric Intensive Care Unit G8ZW, PO Box 22660, 1100 DD Amsterdam, the Netherlands. j.b.vanwoensel@amc.uva.nl
Lutter
René
R
Biezeveld
Maarten  H
M
Dekker
Tamara
T
Nijhuis
Monique
M
van Aalderen
Wim M
WM
Kuijpers
Taco W
TW
D001483:Base Sequence; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis*; D008297:Male; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011336:Probability; D012367:RNA, Viral / Q000032:analysis; D012121:Respiration, Artificial; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000302:isolation & purification; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D014132:Trachea / Q000737:chemistry / Q000821:virology*; D016896:Treatment Outcome; D019562:Viral Load
D016209:Interleukin-8; D012367:RNA, Viral; D003907:Dexamethasone